Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Monday, September 20, 2021 10:27:25 AM
Hilarious: "1) No way brilacidin will be launched as a result of a 120 patient Phase II study, even if the results are spectacular (they won't be, at least not in the sense you imply)."
Brilacidin is on target for EUA with 120 patient trials...If it meets TOPLINE and proves to be as efficacious as expected. AFTER ALL...REMDESIVIR RECEIVED EUA AFTER FAUCI CHEATED FOR IT...switched TOP-LINE of TRAILS when Remedsivir was obviously failing on its original and urged EUA from the FDA...NOW IS REPORTED THAT IT WAS USELESS ALL ALONG...and even TOXIC.
MORE HILARIOUS... "2) FDA, like all smart people, know that an ounce of prevention is worth a pound of cure. Any therapeutic will always be a second line of defense after vaccines have failed to prevent a breakthrough infection"
...FDA "Smart People"???... KNOWS that an "ONCE OF PREVENTION IS WORTH A POUND OF CURE"...this is the SAME FDA APPROVING A "FAILED" and TOXI DRUG into the veins of the vulnerable?
"SMART PEOPLE"...maybe more like "COMPROMISED AND CONFLICTED" with BP who let Fauci pull a fast one on them...or were they co-conspirators?! (Even more Dangerous...if they ARE SMART...then they knew all along about REMDESIVIR's failures and toxicity...which is unfortunately likely.)
How smart will they look when they are forced to REVOKE REMDESIVIR'S APPROVAL?
...and ANOTHER AMUSING STATEMENT: therapeutic "will always be a second line of defense after vaccines have failed to prevent a breakthrough infection."
Brilacidin, due to its RBL results, is EXPECTED AlSO TO BE the FIRST LINE...PROPHYLACTIC!...IMO will prove second to none.
BRILAICIDIN's Prophylactic mechanism IS THE Big Threat to the BP Vaccine monopoly!
A Very entertaining post... It gave me a big laugh!
KNOW WHAT YOU OWN...
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM